Literature DB >> 29146692

Prediction of 90Y Radioembolization Outcome from Pretherapeutic Factors with Random Survival Forests.

Michael Ingrisch1, Franziska Schöppe2, Karolin Paprottka2, Matthias Fabritius2, Frederik F Strobl2, Enrico N De Toni3, Harun Ilhan4, Andrei Todica4, Marlies Michl5, Philipp Marius Paprottka2.   

Abstract

Our objective was to predict the outcome of 90Y radioembolization in patients with intrahepatic tumors from pretherapeutic baseline parameters and to identify predictive variables using a machine-learning approach based on random survival forests.
Methods: In this retrospective study, 366 patients with primary (n = 92) or secondary (n = 274) liver tumors who had received 90Y radioembolization were analyzed. A random survival forest was trained to predict individual risk from baseline values of cholinesterase, bilirubin, type of primary tumor, age at radioembolization, hepatic tumor burden, presence of extrahepatic disease, and sex. The predictive importance of each baseline parameter was determined using the minimal-depth concept, and the partial dependency of predicted risk on the continuous variables bilirubin level and cholinesterase level was determined.
Results: Median overall survival was 11.4 mo (95% confidence interval, 9.7-14.2 mo), with 228 deaths occurring during the observation period. The random-survival-forest analysis identified baseline cholinesterase and bilirubin as the most important variables (forest-averaged lowest minimal depth, 1.2 and 1.5, respectively), followed by the type of primary tumor (1.7), age (2.4), tumor burden (2.8), and presence of extrahepatic disease (3.5). Sex had the highest forest-averaged minimal depth (5.5), indicating little predictive value. Baseline bilirubin levels above 1.5 mg/dL were associated with a steep increase in predicted mortality. Similarly, cholinesterase levels below 7.5 U predicted a strong increase in mortality. The trained random survival forest achieved a concordance index of 0.657, with an SE of 0.02, comparable to the concordance index of 0.652 and SE of 0.02 for a previously published Cox proportional hazards model.
Conclusion: Random survival forests are a simple and straightforward machine-learning approach for prediction of overall survival. The predictive performance of the trained model was similar to a previously published Cox regression model. The model has revealed a strong predictive value for baseline cholinesterase and bilirubin levels with a highly nonlinear influence for each parameter.
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  bilirubin; cholinesterase; prediction; radioembolization; random survival forest

Mesh:

Substances:

Year:  2017        PMID: 29146692     DOI: 10.2967/jnumed.117.200758

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  5 in total

1.  Artificial intelligence and radiomics in nuclear medicine: potentials and challenges.

Authors:  Cumali Aktolun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12       Impact factor: 9.236

2.  Research on E-Commerce Database Marketing Based on Machine Learning Algorithm.

Authors:  Nie Chen
Journal:  Comput Intell Neurosci       Date:  2022-06-29

3.  A Machine Learning-Based Model to Predict Survival After Transarterial Chemoembolization for BCLC Stage B Hepatocellular Carcinoma.

Authors:  Huapeng Lin; Lingfeng Zeng; Jing Yang; Wei Hu; Ying Zhu
Journal:  Front Oncol       Date:  2021-03-02       Impact factor: 6.244

4.  Machine Learning Algorithms to Distinguish Myocardial Perfusion SPECT Polar Maps.

Authors:  Erito Marques de Souza Filho; Fernando de Amorim Fernandes; Christiane Wiefels; Lucas Nunes Dalbonio de Carvalho; Tadeu Francisco Dos Santos; Alair Augusto Sarmet M D Dos Santos; Evandro Tinoco Mesquita; Flávio Luiz Seixas; Benjamin J W Chow; Claudio Tinoco Mesquita; Ronaldo Altenburg Gismondi
Journal:  Front Cardiovasc Med       Date:  2021-11-11

5.  Random Survival Forests to Predict Disease Control for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib.

Authors:  Bin-Yan Zhong; Zhi-Ping Yan; Jun-Hui Sun; Lei Zhang; Zhong-Heng Hou; Xiao-Li Zhu; Ling Wen; Cai-Fang Ni
Journal:  Front Mol Biosci       Date:  2021-05-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.